Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD

NCT06713239 · View on ClinicalTrials.gov ↗

Study Summary

PARAMOUNT is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary atherosclerotic plaque assessment by AI-enabled quantitative software improves: certainty for diagnosis of CAD, control of CAD risk factors and efficiency of ICA referral with appropriate PCI compared to the usual care strategy based on current AHA/ACC guidelines for care of symptomatic patients with suspicion of CAD.

Conditions Studied

Interventions

  • DEVICE Cleerly Labs and Cleerly ISCHEMIA

Study Locations (20)

California

  • Valiance Clinical Research- Huntington Park — Huntington Park
  • Cardiovascular Institute of San Diego — San Diego
  • Valiance Clinical Research- Tarzana — Tarzana
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center — Torrance

Florida

  • Tampa Cardiovascular Interventions and Research — Tampa
  • Flourish Research — Winter Park

Alabama

  • Cardiology Associates of Mobile — Mobile

Colorado

  • Intermountain Health Saint Joseph Hospital — Broomfield

Illinois

  • Endeavor Health Clinical Operations — Evanston

Iowa

  • MercyOne Des Moines Medical Center — West Des Moines

Kentucky

  • Saint Elizabeth Medical Center — Edgewood

Louisiana

  • Tulane University — New Orleans

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2024-12-18
Est. Completion 2026-10
Phase NA

Sponsor

Cleerly

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06713239

The ClinicalTrials.gov registry entry for NCT06713239 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cleerly, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention — of which Cleerly Labs and Cleerly ISCHEMIA is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06713239 reports 20 study locations spanning 16 distinct geographic areas — top geographies include California, Florida, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06713239 about?

NCT06713239 is a clinical study titled "A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD". PARAMOUNT is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary atherosclerotic plaque assessment by AI-enabled quantitative software improves: cer...

What is the current status of trial NCT06713239?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2024-12-18. Estimated completion is 2026-10.

What conditions does trial NCT06713239 study?

This clinical trial studies the following conditions: Coronary Artery Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06713239?

The interventions under investigation include: Cleerly Labs and Cleerly ISCHEMIA (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06713239?

This trial is sponsored by Cleerly, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06713239 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial